131
Participants
Start Date
February 28, 2013
Primary Completion Date
September 30, 2014
Study Completion Date
September 30, 2014
GSK239512
White to almost white, round tablets. Once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
Placebo
White to almost white, round tablets. Once daily orally.
GSK Investigational Site, Sofia
GSK Investigational Site, Sofia
GSK Investigational Site, Sofia
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Hamburg
GSK Investigational Site, Vinnitsa
GSK Investigational Site, Hamburg
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Majadahonda (Madrid)
GSK Investigational Site, Málaga
GSK Investigational Site, Poltava
GSK Investigational Site, Seville
GSK Investigational Site, Lutsk
GSK Investigational Site, Münster
GSK Investigational Site, Cologne
GSK Investigational Site, Kharkiv
GSK Investigational Site, Alzenau in Unterfranken
GSK Investigational Site, Ivano-Frankivsk
GSK Investigational Site, Lviv
GSK Investigational Site, Unterhaching
GSK Investigational Site, Donetsk
GSK Investigational Site, Ulm
GSK Investigational Site, Calgary
GSK Investigational Site, Edmonton
GSK Investigational Site, Ottawa
GSK Investigational Site, Gatineau
GSK Investigational Site, Montreal
GSK Investigational Site, Jihlava
GSK Investigational Site, Olomouc
GSK Investigational Site, Teplice
GSK Investigational Site, Dresden
GSK Investigational Site, Leipzig
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
GSK Investigational Site, Stockholm
GSK Investigational Site, Kyiv
GSK Investigational Site, London
GSK Investigational Site, London
GSK Investigational Site, Romford
GSK Investigational Site, Sheffield
Lead Sponsor
GlaxoSmithKline
INDUSTRY